NCT05525611View on ClinicalTrials.gov

Cabergoline as a Preventive Treatment for Chronic Migraine

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 5, 2022

Primary Completion Date

June 13, 2023

Study Completion Date

August 8, 2023

Conditions
Migraine
Interventions
DRUG

Cabergoline 0.5 MG

Cabergoline 0.5 mg once a week in 12 weeks

OTHER

Placebo

Placebo once a week in 12 weeks

Trial Locations (1)

8200

Medical Research Laboratory, Department of Clinical Medicine, Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus N

All Listed Sponsors
lead

University of Aarhus

OTHER